Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

161. A Systematic Review of The Prevalence of Hepatitis B Among Blood Donors in Ghana and Nigeria Full Text available with Trip Pro

A Systematic Review of The Prevalence of Hepatitis B Among Blood Donors in Ghana and Nigeria dergipark.gov.tr Lütfen https://dergipark.org.tr kullanınız DergiPark bundan 3 yıl önce yeni adresi olan dergipark.org.tr 'ye taşındı. Bu yıl içinde dergipark.gov.tr adresini desteklemeyi bırakmayı planlıyoruz, bu nedenle bağlantılarınızı dergipark.org.tr içerecek şekilde güncellemenizi rica ediyoruz. Please use https://dergipark.org.tr DergiPark moved to its new home at dergipark.org.tr three years ago

2018 Ankara Medical Journal

162. Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta-analysis Full Text available with Trip Pro

Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta-analysis Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta‐analysis - Bjerring, PN - 2018 | Cochrane Library Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so (...) Library website. Cancel Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet Scolaris Content Display Scolaris Content Display Read comments on this Protocol(0) Cochrane Clinical Answers Editorials Podcasts Special Collections Intervention - Protocol Medical interventions for prevention and treatment of hepatic encephalopathy in adults with cirrhosis: a network meta‐analysis Version published: 21 December 2018 Collapse all Expand all Abstract This is a protocol

2018 Cochrane Database of Systematic Reviews

163. Drugs for hepatitis C: it's time to slash prices!

Drugs for hepatitis C: it's time to slash prices! Prescrire IN ENGLISH - Spotlight ''Drugs for hepatitis C: it's time to slash prices!'', 1 December 2018 {1} {1} {1} | | > > > Drugs for hepatitis C: it's time to slash prices! Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Drugs for hepatitis C: it's time to slash prices! The high prices (...) of hepatitis C drugs are an obstacle to treatment for most of the people around the world who are infected by the virus. When so-called direct-acting antiviral drugs against hepatitis C came onto the market around 2015, some stakeholders hailed them as a means of eradicating this disease. Sofosbuvir (Sovaldi°) was marketed in the United States at the exorbitant price of 1000 dollars per day, reflecting the company's strategy of seeking maximum profits in the richest countries and not eradication

2018 Prescrire

164. Chronic hepatitis B virus infection. (Abstract)

Chronic hepatitis B virus infection. Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical (...) . With current vaccines, therapies, and an emphasis on improving linkage to care, WHO's goal of eliminating hepatitis B virus as a global health threat by 2030 is achievable.Copyright © 2018 World Health Organization. Published by Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.. All rights reserved.

2018 Lancet

165. Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block Full Text available with Trip Pro

Treatment of Adolescents With Chronic Hepatitis C Virus Infection: New Regimen on the Block Editorial to Leung et al. "Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4".

2018 Hepatology communications

166. Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V

Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports (...) – Commission No. A17-55 Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-55 Version 1.0 Sofosbuvir (chronic hepatitis C in adolescents) 11 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

167. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - Addendum to Commission A17-35 1 Translation of addendum A18-05 Sofosbuvir/Velpatasvir/Voxilaprevir (Chronische Hepatitis C) – Addendum zum Auftrag A17-35 (Version 1.0; Status: 25 January 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 January 2018 1.0 Commission: A18-05 Version (...) : Status: IQWiG Reports – Commission No. A18-05 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35 1 Addendum A18-05 Version 1.0 Sofosbuvir/velpatasvir/voxilaprevir – Addendum to Commission A17-35 25 January 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – Addendum to Commission A17-35

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

168. The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis Full Text available with Trip Pro

The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis Background: The harm of liver cirrhosis (LC) is serious, and the development of LC is primarily resulted from chronic hepatitis B virus (HBV) in high-risk such as China and Africa and chronic hepatitis C virus (HCV) in developed areas such as United States (...) ." /> Background: The harm of liver cirrhosis (LC) is serious, and the development of LC is primarily resulted from chronic hepatitis B virus (HBV) in high-risk such as China and Africa and chronic hepatitis C virus (HCV) in developed areas such as United States." /> Toggle navigation Collaborations Publish Now Registrations Manuscript Guidelines Other Services Policies Policies ISSN: 2641-2977 Research Article Open Access Peer-Reviewed The correlation between serum cytokine levels and liver cirrhosis

2018 Archives of Hepatitis Research

169. Hepatic Encephalopathy in Patients in Lviv (Ukraine) Full Text available with Trip Pro

Hepatic Encephalopathy in Patients in Lviv (Ukraine) Hepatic encephalopathy (HE) research has long been impeded by the vague definition of this disabling complication of liver failure. This article provides an overview of the etiology and impact of HE on neuromuscular functions as well as its role in the development of infections and anemia.This was a descriptive study conducted in 36 patients with HE. Close monitoring of these patients was done by checking on several parameters.The etiological (...) distribution: alcohol (67%), hepatitis C virus (HCV; 17%), HCV and alcohol (8%), hepatitis B virus (HBV; 3%), HBV and alcohol (3%), HBV and HCV (6%), and cryptogenic (3%). The laboratory results indicated an elevation of De Ritis level in 69% of cases and in 92% of total bilirubin values. The Halstead-Reitan (H-R) test score with regards to gender indicated that more than half of the patients had a score of 2, while only few cases received the scores 3 and 4. The frequency of H-R score with regards

2018 Journal of translational internal medicine

170. Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy Full Text available with Trip Pro

Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy There is a rising prevalence of hepatitis C (HCV) among women of child-bearing age nationally, which prompted a recommendation by national guidelines to screen all women for HCV during pregnancy. Women with HCV during pregnancy are at risk of perinatal transmission of HCV. Directly acting antiviral (DAA) therapy during pregnancy can potentially reduce the risk of perinatal transmission as well as cure women while

2018 Hepatology communications

171. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les

2018 Haute Autorite de sante

172. Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease Full Text available with Trip Pro

Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adults. This study examined the relationship between hepatic nuclear receptor (NR) expression and histologic features of NAFLD. Drugs targeting a variety of NRs for nonalcoholic steatohepatitis (NASH) are in clinical trials. Liver messenger RNA was isolated from 40

2018 Hepatology communications

173. Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis Full Text available with Trip Pro

Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis Preimplantation factor (PIF) is an evolutionary conserved peptide secreted by viable embryos which promotes maternal tolerance without immune suppression. Synthetic PIF (sPIF) replicates native peptide activity. The aim of this study was to conduct the first-in-human trial of the safety, tolerability, and pharmacokinetics of sPIF in patients with autoimmune (...) hepatitis (AIH). We performed a randomized, double-blind, placebo-controlled, prospective phase I clinical trial. Patients were adults with documented AIH with compensated chronic liver disease. Diagnosis of AIH was confirmed by either a pretreatment International Criteria for the Diagnosis of AIH score of 15 or more, or a posttreatment score of 17 or more. Patients were divided into three dosing cohorts (0.1, 0.5, or 1.0 mg/kg) of 6 patients in each group. Three patients in each group had normal liver

2018 Hepatology communications Controlled trial quality: predicted high

174. Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report Full Text available with Trip Pro

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report We report the case of a woman with chronic hepatitis C and idiopathic thrombocytopenic purpura (ITP) who developed autoimmune hepatitis (AIH) during antiviral therapy with ledipasvir (LDV)/sofosbuvir (SOF). The onset of acute hepatitis rose two weeks after starting treatment with LDV/SOF when HCV-RNA tested negative, suggesting a link between rapid HCV clearance and de novo autoimmune diseases. Conclusion (...) : This case report proposes new immunologic scenarios in patients with hepatitis C virus (HCV) with laboratory or clinical signs of autoimmunity during direct-acting antiviral (DAA) therapy.

2018 Hepatology communications

175. CEACAM1 Is Associated With the Suppression of Natural Killer Cell Function in Patients With Chronic Hepatitis C Full Text available with Trip Pro

CEACAM1 Is Associated With the Suppression of Natural Killer Cell Function in Patients With Chronic Hepatitis C Natural killer cells (NK cells) play an essential role in the immunological mechanism underlying chronic hepatitis C (CHC). Impairment of NK cell function facilitates persistent infection with hepatitis C virus (HCV) and hepatocellular carcinogenesis. However, the mechanism by which NK cell activity is suppressed in CHC is not completely understood. In this study, we focused (...) on carcinoembryonic antigen-related cell-adhesion molecule 1 (CEACAM1). CEACAM1 is thought to suppress NK cell function. We examined the effect of CEACAM1 on NK cell function in CHC. We investigated the function of CEACAM1 in vitro using Huh7.5.1 cells and the HCV-Japanese fulminant hepatitis (JFH)-1 strain. We analyzed serum CEACAM1 level, NK cell function, and CEACAM1 messenger RNA (mRNA) level in human liver samples. Levels of CEACAM1 on the cell surface, CEACAM1 mRNA levels, and soluble CEACAM1 levels

2018 Hepatology communications

176. Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population Full Text available with Trip Pro

Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population Recent hepatitis C virus (HCV) guidelines recommend disease monitoring and hepatocellular carcinoma (HCC) screening in patients with advanced fibrosis after a sustained virologic response (SVR) with direct-acting antiviral (DAA) therapy. However, data on practice patterns in this setting is lacking. We aimed to characterize disease monitoring and HCC screening practices post-SVR in an underserved HCV

2018 Hepatology communications

177. Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir Full Text available with Trip Pro

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir Ledipasvir-sofosbuvir, a once-a-day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with the use of the medication. We assessed the rates of AKI in patients undergoing ledipasvir-sofosbuvir in a large, urban tertiary care center

2018 Hepatology communications

178. Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion Full Text available with Trip Pro

Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion 30288471 2018 11 14 2471-254X 2 10 2018 Oct Hepatology communications Hepatol Commun Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion. 1168-1171 10.1002/hep4.1249 Wang Jie J State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences Peking University Health Science Center Beijing China. Chen Xiangmei

2018 Hepatology communications

179. Serum Interleukin‐8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Full Text available with Trip Pro

Serum Interleukin‐8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease The severity of hepatic fibrosis is the primary predictor of liver-related morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). Unfortunately, noninvasive serum biomarkers for NAFLD-associated fibrosis are limited. We analyzed baseline serum samples for 24 cytokines of 97 patients with biopsy-proven NAFLD (...) . These patients were prospectively enrolled in a clinical study (ClinicalTrials.gov NCT00794716) to identify cytokines associated with liver fibrosis in patients with nonalcoholic steatohepatitis. Patients were stratified according to severity of hepatic fibrosis (mild, stage 0-1, n = 37; moderate, stage 2, n = 40; and advanced, stage 3-4, n = 20) while controlling for age, race, sex, body mass index, and diabetes mellitus. Interleukin-8 (IL-8), osteopontin (OPN), and monocyte chemoattractant protein 1 (MCP1

2018 Hepatology communications

180. Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C Full Text available with Trip Pro

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C Sustained virologic response (SVR) after direct-acting antiviral (DAA) therapy for chronic hepatitis C results in significant decreases in liver stiffness measured by transient elastography (TE). The aim of this study was to clarify if TE can guide post-SVR management in patients with advanced fibrosis or cirrhosis prior to treatment as current guidelines are unclear (...) on the role of TE after SVR. In total, 84 patients with hepatitis C virus and advanced fibrosis or cirrhosis and from a single center underwent DAA treatment and achieved SVR. Overall, 62% had improved liver stiffness that was consistent with regression of at least one stage of fibrosis. In the cirrhosis group, 48% showed fibrosis regression by at least two stages by TE (<9.5 kPa). In the F3 fibrosis group, 39% regressed by at least two stages (<7 kPa). The median time from SVR to regression by TE was 1

2018 Hepatology communications